Spyre Therapeutics, Inc.
Clinical trials sponsored by Spyre Therapeutics, Inc., explained in plain language.
A biotechnology company developing antibody therapies for inflammatory bowel disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug SPY002-072 aims to tame multiple inflammatory joint diseases Results expected Oct 2026 (estimated) May already have reported ↗
- New drug SPY003-207 tested in humans for first time Results expected Nov 2026 (estimated)
- New antibody cocktail aims to tame ulcerative colitis Results expected Jun 2027 (estimated) May already have reported ↗
-
New antibody cocktail aims to tame ulcerative colitis for good
Disease control By invitation onlyThis study is testing three long-acting antibodies, alone or in combination, in 645 people with ulcerative colitis. The goal is to see if they are safe and can improve bowel inflammation over 48 weeks. Participants are joining from a previous study and may have already seen some …
Phase 2 • Sponsor: Spyre Therapeutics, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug SPY002-072 aims to tame multiple inflammatory joint diseases
Disease control OngoingThis Phase 2 study tests an experimental drug called SPY002-072 in 285 adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis. Participants receive either the drug or a placebo, and researchers measure changes in disease ac…
Phase 2 • Sponsor: Spyre Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug SPY003-207 tested in humans for first time
Knowledge-focused OngoingThis early-stage trial tests the safety of a single dose of SPY003-207 in 59 healthy adults. Participants are randomly assigned to receive either the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. The goal is to gather initial…
Phase 1 • Sponsor: Spyre Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC